Skip to main content
Loading research indexW

A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States

clinicaltrials2026-10-16Source metadata onlyOpen source ↗
INVESTOR TAKEAWAY

Advanced Unresectable Gastric Adenocarcinoma; Esophageal Squamous Cell Carcinoma; Advanced Gastroesophageal Adenocarcinoma

ORIGINAL PAPER

A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States

WHAT WE KNOW

Advanced Unresectable Gastric Adenocarcinoma; Esophageal Squamous Cell Carcinoma; Advanced Gastroesophageal Adenocarcinoma

WATCH NEXT

Expected trial readout: 2031-12-31

EVIDENCE

What the evidence supports so far

Research signals

Classification pending.

What remains unverified

The full methodology, effect size, and limitations still require analyst review.

Company impact remains unverified until a direct economic transmission is established.